

# **Justification Document for the Selection of a CoRAP Substance**

### -Update-

**Substance Name (public name):** 1,1,1,3,5,5,5-heptamethyl-3-

[(trimethylsilyl)oxy]trisiloxane

**EC Number:** 241-867-7

**CAS Number:** 17928-28-8

Authority: NO CA

**Date:** 22/03/2016 (UK)

20/03/2018 (1. Update) (UK)

19/03/2019 (2. Update) (NO)

#### **Cover Note**

This document has been prepared by the evaluating Member State given in the CoRAP update.

# **Table of Contents**

1		OF THE SUBSTANCE er identifiers of the substance	3	
2	OVERVIE	W OF OTHER PROCESSES / EU LEGISLATION	5	
3	3.1 Clas	INFORMATION (INCLUDING CLASSIFICATION) sification Harmonised Classification in Annex VI of the CLP	6	
	3.1.2	Self classification	6	
	3.1.3 CLP	Proposal for Harmonised Classification in Annex VI of the 6		
4	INFORMATION ON (AGGREGATED) TONNAGE AND USES 4.1 Tonnage and registration status 4.2 Overview of uses			
5.	5.1.Lega 5.2. Sela CoR 5.3 Initi Eval 5.4 Prel requ	al grounds for concern to be clarified under Substance luation iminary indication of information that may need to be uested to clarify the concern	8	
	5.5 Pote	ential follow-up and link to risk management	9	

# 1 IDENTITY OF THE SUBSTANCE

#### 1.1 Other identifiers of the substance

**Table: Other Substance identifiers** 

EC name (public):	1,1,1,3,5,5,5-heptamethyl-3- [(trimethylsilyl)oxy]trisiloxane		
IUPAC name (public):	1,1,1,3,5,5,5-heptamethyl-3- [(trimethylsilyl)oxy]trisiloxane		
Index number in Annex VI of the CLP Regulation:	Not applicable		
Molecular formula:	C <sub>10</sub> H <sub>30</sub> O <sub>3</sub> Si <sub>4</sub>		
Molecular weight or molecular weight range:	310.69		
Synonyms:	TMF-1.5		

**Type of substance**  $\square$  Mono-constituent  $\square$  Multi-constituent  $\square$  UVCB

#### **Structural formula:**

EC no 241-867-7 MSCA - NO Page 3 of 9

## 1.2 Similar substances/grouping possibilities

The structurally related chemicals hexamethyldisiloxane, octamethyltrisiloxane, decamethyltetrasiloxane and dodecamethyltetrasiloxane could be included to form a category for evaluation.

Name	CAS No	EC No	Comments
Hexamethyldisiloxane (L2)	107-46-0	203-492-7	Registered, SEV by UKCA in 2013
Octamethyltrisiloxane (L3)	107-51-7	203-497-4	Registered, SEV by UKCA in 2015
Decamethyltetrasiloxane (L4)	141-62-8	205-491-7	Registered, SEV by UKCA in 2015
Dodecamethyltetrasiloxane (L5)	141-63-9	205-492-2	Registered, SEV by UKCA in 2015

#### Structural formula:

Hexamethyldisiloxane (L2)	Si
Octamethyltrisiloxane (L3)	Si Si Si
Decamethyltetrasiloxane (L4)	
Dodecamethyltetrasiloxane (L5)	

EC no 241-867-7 MSCA - NO Page 4 of 9

# **2 OVERVIEW OF OTHER PROCESSES / EU LEGISLATION**

**Table: Completed or ongoing processes** 

RMOA		$\square$ Risk Management Option Analysis (RMOA)		
	Evaluation	⊠Compliance check, Final decision		
		⊠Testing proposal, ongoing		
ssses		☐ CoRAP and Substance Evaluation		
REACH Processes	Authorisation	☐ Candidate List		
REA	Authoi	☐ Annex XIV		
	Restri -ction	☐ Annex XVII		
Harmonised C&L		☐ Annex VI (CLP) (see section 3.1)		
sses other slation		☐ Plant Protection Products Regulation  Regulation (EC) No 1107/2009		
Processes under other EU legislation		☐ Biocidal Product Regulation  Regulation (EU) 528/2012 and amendments		
us ion		☐ Dangerous substances Directive Directive 67/548/EEC (NONS)		
Previous legislation		☐ Existing Substances Regulation  Regulation 793/93/EEC (RAR/RRS)		
JNEP) ckholm vention POPs		☐ Assessment		
(UNEP) Stockholm convention (POPs		☐ In relevant Annex		
Other processes / EU legislation		$\square$ Other (provide further details below)		

D4 and D5 have been agreed to meet the PBT/vPvB criteria and an Annex XV restriction dossier for D4, D5, D6 is in progress, which may affect the supply of decamethyltetrasiloxane if this is used as a substitute in the future.

L2, L3, L4 and L5 are already subject to substance evaluation under REACH.

#### 3 HAZARD INFORMATION (INCLUDING CLASSIFICATION)

#### 3.1 Classification

#### 3.1.1 Harmonised Classification in Annex VI of the CLP

The substance is not classified in Annex VI of Regulation (EC) No 1272/2008

#### 3.1.2 Self classification

- In the registration: not classified
- The following hazard classes are in addition notified among the aggregated self classifications in the C&L Inventory:

```
Flam. Liq. 3 H226
Skin Irrit. 2 H315
Eye Irrit. 2 H319
STOT SE 3 H335 (target organ: "respiratory tract" or "not provided")
```

# 3.1.3 Proposal for Harmonised Classification in Annex VI of the CLP

No proposal according to registry of intention (checked May 2015)

#### 4 INFORMATION ON (AGGREGATED) TONNAGE AND USES<sup>1</sup>

#### 4.1 Tonnage and registration status

**Table: Tonnage and registration status** 

From ECHA dissemination site*				
□ Full registration(s) (Art. 10)		☐ Intermediate registration(s) (Art. 17 and/or 18)		
Tonnage band (as per dissemina	ntion s	te)		
□ 1 - 10 tpa	⊠ 10 – 100 tpa		□ 100 – 1000 tpa	
□ 1000 – 10,000 tpa	□ 10	0,000 – 100,000 tpa	$\square$ 100,000 - 1,000,000 tpa	
□ 1,000,000 - 10,000,000 tpa				
□ <1 >+ tpa (e.g. 10+ ; 100+ ; 10,000+ tpa) □ Confidential				
Joint submission				

 $\frac{\text{https://echa.europa.eu/documents/10162/22308542/manual dissemination en.pdf/7e0b8}}{7c2-2681-4380-8389\text{-cd655569d9f0}}$ 

#### 4.2 Overview of uses

The following uses are identified on the ECHA dissemination site: cosmetics and personal care products, and laboratory reagent. These cover industrial use, professional use and consumer use.

The primary interest in the substance evaluation is the use of cosmetics and personal care products as this is potentially a down-the-drain source of environmental exposure. The significance of the other use will be assessed as part of the evaluation. It is expected that there will be similarities with the exposure assessments of HMDS (L2) (already evaluated), L3-L5 (being evaluated in 2015) and the cyclic siloxanes D4 and D5 (both subject to a risk management options analysis and restriction dossier).

**Table: Uses** 

#### Part 1:

	$\boxtimes$	$\boxtimes$	$\boxtimes$	$\boxtimes$	☐ Article	☐ Closed
Manufacture	Formulation	Industrial	Professional	Consumer	service life	system
		use	use	use		

<sup>\*</sup>the total tonnage band has been calculated by excluding the intermediate uses, for details see the Manual for Dissemination and Confidentiality under REACH Regulation (section 2.6.11):

<sup>&</sup>lt;sup>1</sup> Based on ECHA dissemination site accessed 14.11.2018.

5. JUSTIFICATION FOR THE SELECTION OF THE CANDIDATE CORAP **SUBSTANCE** 5.1. Legal basis for the proposal  $\boxtimes$  Article 44(2) (refined prioritisation criteria for substance evaluation) **5.2. Selection criteria met** (why the substance qualifies for being in CoRAP) ☐ Fulfils criteria as CMR/ Suspected CMR ☐ Fulfils criteria as Sensitiser/ Suspected sensitiser ☐ Fulfils criteria as potential endocrine disrupter ☑ Fulfils criteria as PBT/vPvB / Suspected PBT/vPvB  $\Box$  Fulfils criteria high (aggregated) tonnage (*tpa* > 1000) □ Fulfils exposure criteria ☐ Fulfils MS's (national) priorities 5.3 Initial grounds for concern to be clarified under Substance **Evaluation** Hazard based concerns Suspected CMR<sup>2</sup> CMR ☐ Potential endocrine disruptor  $\Box$  C  $\Box$  M  $\Box$  R  $\Box$  C  $\Box$  M  $\Box$  R ☐ Sensitiser ☐ Suspected Sensitiser<sup>2</sup> ☐ Other (please specify below) ☐ PBT/vPvB Suspected PBT/vPvB<sup>2</sup> Exposure/risk based concerns ☐ Exposure of sensitive ☐ Consumer use populations ☐ Exposure of ☐ Exposure of workers ☐ Cumulative exposure environment ☐ High RCR ☐ High (aggregated) tonnage ☐ Other (please specify below) The substance screens as vPvB based on the results from a ready biodegradation study and predicted log Kow. The registrant's PBT assessment indicates the substance "The screening criteria for persistence (P/vP) in the sediment compartment are met.". However, a request to waive the environmental simulation studies for water, sediment and soil for the substance have been included in the registration dossier. Characteristics of other siloxanes such as D4, D5 and HMDS (L2) suggest that this group of substances has the potential to be persistent in sediment. Therefore as well as clarifying P properties, sediment risks will also be investigated.

EC no 241-867-7 MSCA - NO Page 8 of 9

The measured bioconcentration factor in fish at steady state is 3500 L/kg according to the registration dossier. This exceeds the Annex XIII B criterion. It is not known if this value has been corrected for growth or lipid normalised, and it is possible that the value may be higher once this has been done. The range of BCF results is between 1500-9600 L/kg.

The chronic fish endpoint is fulfilled using read-across to a test that only investigated mortality. The validity of this test will be assessed as the endpoint is important for the T assessment.

1,1,1,3,5,5,5-heptamethyl-3-[(trimethylsilyl)oxy]trisiloxane is registered with uses including professional and consumer personal care products, which suggests a wide dispersive use pattern. As the substance could be a potential replacement for D4 and D5, the supply volume of 1,1,1,3,5,5,5-heptamethyl-3-[(trimethylsilyl)oxy] could increase if uses of those substances are restricted.

The evaluation will be targeted to the environment but during the PBT assessment the human health endpoints relevant to the T criterion will be assessed.

5.4 Preliminary indication of information that may need to be requested clarify the concern						
$\square$ Information on toxicological properties	$\square$ Information on physico-chemical properties					
☑Information on fate and behaviour	☑ Information on exposure					
☐ Information on ecotoxicological propertion	es					
☐ Information ED potential	☐ Other (provide further details below)					
Testing to assess persistence in sediment, for example OECD 308 Aerobic and Anaerobic Transformation in Aquatic Sediment Systems.  Further information on releases from relevant parts of the life cycle (may include a request for monitoring data).  Further data to clarify any sediment risks.						
5.5 Potential follow-up and link to risk management						
☐ Harmonised C&L ☐ Restriction ☐ Authorisation ☐ Other (provide further details)						
To be determined following substance evaluation. However, if the PBT/vPvB concern is confirmed, it will not be desirable to allow the replacement of D4 and D5 by this substance in						

personal care products and cosmetics, so a similar restriction approach might be required.

Suspected PBT: Potentially Persistent, Bioaccumulative and Toxic

<sup>&</sup>lt;sup>2</sup> <u>CMR/Sensitiser</u>: known carcinogenic and/or mutagenic and/or reprotoxic properties/known sensitising properties (according to CLP harmonized or registrant self-classification or CLP Inventory) <u>Suspected CMR/Suspected sensitiser</u>: suspected carcinogenic and/or mutagenic and/or reprotoxic properties/suspected sensitising properties (not classified according to CLP harmonized or registrant self-classification)